Roche Holding AG (SWX:ROP)

Market Cap	240.33B -1.4%
Revenue (ttm)	63.36B +1.5%
Net Income	12.88B +55.6%
EPS	16.04 +55.6%
Shares Out	795.62M
PE Ratio	18.76
Forward PE	14.85
Dividend	9.80 (3.26%)
Ex-Dividend Date	Mar 12, 2026

Volume	935,991
Average Volume	1,422,730
Open	294.60
Previous Close	300.90
Day's Range	291.00 - 305.90
52-Week Range	231.90 - 374.90
Beta	0.21
RSI	26.68
Earnings Date	Apr 23, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1896
• Employees: 103,249
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ROP

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.